Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003
Thursday announced the acquisition of Xbrane Biopharma AB’s R&D operations and a biosimilar candidate, establishing a footprint in the Swedish life science sector.
Icelandic Biotech Company Alvotech to Explore Listing in Stockholm
Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.
Nasdaq2d
Alvotech Expands Biosimilar Development Capabilities with Acquisition of Xbrane Biopharma R&D Operations
Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...
Morningstar2d
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
"Alvotech has a best-in-class biosimilars manufacturing site in Iceland, both for drug substance and drug products. At the same time, our strong in-house R&D capabilities have put Alvotech in a ...
Drug Store News1d
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars
After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.
Pharmabiz1d
Alvotech acquires Xbrane’s R&D operations in Sweden and further affirms its global leadership position in biosimilars development and production
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the acquisition of Xbrane Biopharma AB’s (Xbrane) R&D ...
Dr. Reddy’s, Alvotech announce FDA acceptance of AVT03 BLA
Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission for AVT03, developed ...
Dr. Reddy’s, Alvotech announce FDA acceptance of BLA for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. Food and Drug Administration, FDA, has accepted a 351(k) Biologic ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.